Aerosol Research and Engineering Laboratories Inc. Certificate of Analysis

This certificate of analysis is for testing completed using the **Tadiran Air Care O**₂. The testing certifies that the Tadiran Air Care Device shows high efficacy at reduction of aerosolized **MS2 Bacteriophage** in a bioaerosol test chamber.

Testing Results

Tadiran Air Care O2 MS2 Trial Summary Data

9

Bioaerosol Type	Species (description)	Trial Name	Reduction Type	Trial Time (minutes)				
				30	60	90	120	150
Virus	MS2	T1	Net Log Reduction	-1.79	-3.00	-3.84	-4.67	-4.96
	(RNA E. coli phage)		Net % Reduction	98.3931%	99.9010%	99.9856%	99.9979%	99.9989%
Virus	MS2	Т2	Net Log Reduction	-2.30	-3.41	-3.79	-4.68	-4.95
	(RNA E. coli phage)		Net % Reduction	99.4947%	99.9610%	99.9839%	99.9979%	99.9989%
Virus	MS2	ТЗ	Net Log Reduction	-2.10	-2.88	-3.54	-4.07	-4.85
	(RNA E. coli phage)		Net % Reduction	99.2091%	99.8690%	99.9713%	99.9916%	99.9986%
All Trial Averages			Net Log Reduction	-2.06 +/- 0.25	-3.1 +/- 0.28	-3.73 +/- 0.16	-4.48 +/- 0.35	-4.92 +/- 0.06
All Iffai Averages		Net % Reduction	99.0323% +/- 0.5716%	99.9103% +/- 0.0467%	99.9803% +/- 0.0078%	99.9958% +/- 0.0037%	99.9988% +/- 0.0002%	

Conclusion

The Tadiran Air Care O₂ demonstrated efficacy at reducing MS2 Bacteriophage in the air.

am

March 21, 2021

Date



5

Jamie Balarashti Study Director ARE Labs, Inc.